© 2021 MJH Life Sciences and Pharmacy Times. All rights reserved.
© 2021 MJH Life Sciences™ and Pharmacy Times. All rights reserved.
March 14, 2011
The FDA approved Kapvay (clonidine hydrochloride extended -release) as a monotherapy and adjunctive therapy for the treatment of attention- deficit/hyperactivity disorder in children and adolescents aged 6 to 17 years.